Financials

News Discussions Technicals Seasonals

ISOFOL fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Isofol Medical AB is a biotech company, which engages in the development of the cancer drug Arfolitixorin, intended primarily for the treatment of colorectal cancer. The company was founded in 2008 by Bengt Gustaf Gustavsson and is headquartered in Gothenburg, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

ISOFOL has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company